Skip to main content

Table 4 Association of CHEK2 H371Y with pathological response according to neoadjuvant treatment regimens

From: Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer

Chemotherapy N non-pCR, n (%) pCR, n (%) P-value
Anthracycline 859    0.35
Non-carriers 841 687 (81.7) 154 (18.3)  
Carriers 18 13 (72.2) 5 (27.8)  
Anthracycline-taxane 882    0.032
Non-carriers 872 700 (80.3) 172 (19.7)  
Carriers 10 5 (50.0) 5 (50.0)  
Taxane 593    0.71
Non-carriers 582 461 (79.2) 121 (20.8)  
Carriers 11 8 (72.7) 3 (27.3)  
  1. pCR, pathologic complete response.